Seeing Is Believing
Currently out of the existing stock ratings of Sara Nik, 6 are a BUY (100%).
Analyst Sara Nik, carries an average stock price target met ratio of 25% that have a potential upside of 29.02% achieved within 50 days.
Sara Nik’s has documented 12 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRIS, Curis at 16-Aug-2026.
Analyst best performing recommendations are on MBRX (MOLECULIN BIOTECH).
The best stock recommendation documented was for MBRX (MOLECULIN BIOTECH) at 9/10/2025. The price target of $4 was fulfilled within 99 days with a profit of $5.53 (58.03%) receiving and performance score of 5.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 10-Sep-2025
$22
$18.73 (572.78%)
$4
Buy Since 09-Jun-2025
$4
$0.73 (22.32%)
$4
Buy Since 14-Dec-2023
$8
Hold Since 25-Mar-2025
$4
$0.73 (22.32%)
Buy Since 14-Apr-2021
$30
$26.73 (817.43%)
Which stock is Sara Nik is most bullish on?
Which stock is Sara Nik is most reserved on?
What Year was the first public recommendation made by Sara Nik?